Corient Private Wealth LLC Buys New Shares in CalciMedica, Inc. (NASDAQ:CALC)

Corient Private Wealth LLC purchased a new position in CalciMedica, Inc. (NASDAQ:CALC) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,000 shares of the company’s stock, valued at approximately $135,000. Corient Private Wealth LLC owned approximately 0.28% of CalciMedica as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CALC. Geode Capital Management LLC grew its stake in shares of CalciMedica by 51.2% during the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after acquiring an additional 22,525 shares during the period. Atria Investments Inc raised its stake in CalciMedica by 28.3% during the 4th quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock worth $120,000 after acquiring an additional 7,509 shares during the period. Finally, PVG Asset Management Corp purchased a new position in CalciMedica during the third quarter valued at approximately $67,000.

CalciMedica Stock Up 2.1 %

NASDAQ:CALC opened at $1.95 on Wednesday. CalciMedica, Inc. has a 52 week low of $1.81 and a 52 week high of $6.27. The business’s 50-day simple moving average is $2.34 and its two-hundred day simple moving average is $3.11. The stock has a market cap of $26.29 million, a PE ratio of -1.81 and a beta of 1.20.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. Sell-side analysts anticipate that CalciMedica, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a research report on Tuesday.

CalciMedica Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.